PAB 0.00% 0.7¢ patrys limited

Ann: Patrys Reports Progress on Preclinical Programmes, page-23

  1. 9,497 Posts.
    lightbulb Created with Sketch. 336
    Why are all the risks with this stock on the down side?No different to any other stock.They have a product that works,and enhances other therapies,which didnt work before on their own.It will have it's time,especially if the trial with ONYX goes well.What am I in denial about?
 
watchlist Created with Sketch. Add PAB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.